Gram-positive Bacterial Infections Clinical Trial
Official title:
Linezolid in the Treatment of Penicillin-Resistant Streptococcus Pneumoniae Pneumonia: An Open-Label, Non-Comparator Study
| Verified date | April 2011 |
| Source | Pfizer |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Food and Drug Administration |
| Study type | Interventional |
This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)
| Status | Completed |
| Enrollment | 230 |
| Est. completion date | May 2003 |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 13 Years and older |
| Eligibility |
Other specific inclusion/exclusion criteria may apply. In order to determine eligibility,
further examination by the investigator is necessary. Inclusion Criteria: - Patients must have the signs and symptoms of pneumonia, with a chest xray showing a pneumonia. - The patient must have S. pneumoniae (a specific bacteria) growing in sputum or blood to continue treatment. Exclusion Criteria: - Patients cannot have taken more than one day of another antibiotic before entering this study. - Patients with HIV and a low CD4 count are excluded. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Slovakia | Research Center | Bratislava | |
| Spain | Research Center | Barcelona | |
| Spain | Research Center | Barcelona | |
| Spain | Research Center | Barcelona | |
| Spain | Research Center | Girona | |
| Spain | Research Center | Madrid | |
| Spain | Research Center | Madrid | |
| Spain | Research Center | Madrid | |
| Spain | Research Center | Mataro | Barcelona |
| Spain | Research Center | Mostoles | Madrid |
| Taiwan | Research Center | Kaohsiung | |
| Taiwan | Research Center | Taoyuan | |
| United States | Research Center | Ann Arbor | Michigan |
| United States | Research Center | Baltimore | Maryland |
| United States | Research Center | Baton Rouge | Louisiana |
| United States | Research Center | Charlottesville | Virginia |
| United States | Research Center | Columbus | Ohio |
| United States | Research Center | Dallas | Texas |
| United States | Research Center | Fleetwood | Pennsylvania |
| United States | Research Center | Hackensack | New Jersey |
| United States | Research Center | Harrogate | Tennessee |
| United States | Research Center | Hershey | Pennsylvania |
| United States | Research Center | Houston | Texas |
| United States | Research Center | Jackson | Tennessee |
| United States | Research Center | Jacksonville | Florida |
| United States | Research Center | Knoxville | Tennessee |
| United States | Research Center | Los Angeles | California |
| United States | Research Center | Lubbock | Texas |
| United States | Research Center | Memphis | Tennessee |
| United States | Research Center | Memphis | Tennessee |
| United States | Research Center | Memphis | Tennessee |
| United States | Research Center | Naples | Florida |
| United States | Research Center | Nashville | Tennessee |
| United States | Research Center | Newark | New Jersey |
| United States | Research Center | Ninety Six | South Carolina |
| United States | Research Center | Richmond | Virginia |
| United States | Research Center | Royal Oak | Michigan |
| United States | Research Center | Savannah | Georgia |
| United States | Research Center | Seattle | Washington |
| United States | Research Center | Somerville | New Jersey |
| United States | Research Center | Spartanburg | South Carolina |
| United States | Research Center | Springfield | Illinois |
| United States | Research Center | Springfield | Missouri |
| United States | Research Center | Staten Island | New York |
| United States | Research Center | Stony Brook | New York |
| United States | Research Center | Zanesville | Ohio |
| Lead Sponsor | Collaborator |
|---|---|
| Pfizer |
United States, Slovakia, Spain, Taiwan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | To assess the microbiologic efficacy of linezolid in the treatment of patients with pneumonia caused by penicillin-resistant Streptococcus pneumoniae (PRSP). | |||
| Primary | Additionally, microbiologic efficacy will be assessed in all pneumonia patients infected with S pneumoniae SP) and in those infected with penicillin-sensitive (PSSP) and penicillin-intermediate (PISP) S pneumoniae. | |||
| Secondary | To assess clinical efficacy and safety in pneumonia patients infected with S pneumoniae. |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01412801 -
Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings
|
Phase 2 | |
| Completed |
NCT00501150 -
Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections
|
N/A | |
| Terminated |
NCT00108433 -
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
|
Phase 3 | |
| Not yet recruiting |
NCT06444802 -
Model-informed Precision Dosing for Linezolid
|
Phase 3 | |
| Terminated |
NCT00529282 -
A Study of Ceftobiprole in Patients With Fever and Neutropenia.
|
Phase 3 | |
| Completed |
NCT00079976 -
Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)
|
Phase 3 | |
| Terminated |
NCT00835783 -
Validation Study of Combined Positron Emission Tomography/Computer Tomography to Diagnose Infection and Inflammation
|
N/A | |
| Completed |
NCT00081744 -
Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects
|
Phase 3 | |
| Completed |
NCT03747497 -
Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection
|
Phase 2 | |
| Active, not recruiting |
NCT04911270 -
Clinical Decision Support Tool for Vancomycin Dosing in Children
|
N/A | |
| Completed |
NCT02750761 -
A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)
|
Phase 1 | |
| Completed |
NCT00406198 -
Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis
|
Phase 4 | |
| Completed |
NCT03560440 -
Evaluation of the Dosing Regimen of Vancomycin in Pediatric Patients
|
||
| Completed |
NCT00147511 -
Time To Efficacy and Onset Of Action Of Linezolid
|
Phase 4 | |
| Terminated |
NCT00240747 -
Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients
|
Phase 3 | |
| Not yet recruiting |
NCT04917380 -
The Clinical Character，Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens.
|
||
| Completed |
NCT00736554 -
What is the Prevalence of Methicillin-Resistant Staphylococcus Aureus in Skin and Soft Tissue Infections Presenting to the Emergency Departments of a Canadian Academic Health Care Center?
|
N/A | |
| Completed |
NCT03361163 -
Controlled Human Infection for Vaccination Against Streptococcus Pyogenes
|
Phase 1 | |
| Completed |
NCT00167960 -
Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit
|
Phase 4 | |
| Completed |
NCT00874367 -
Early-Onset Sepsis Surveillance Study
|
N/A |